The public health impact of COVID-19 variants of concern on the effectiveness of contact tracing in Vermont, United States.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 Aug 2024
Historique:
received: 27 09 2023
accepted: 25 07 2024
medline: 2 8 2024
pubmed: 2 8 2024
entrez: 1 8 2024
Statut: epublish

Résumé

Case investigation and contact tracing (CICT) are public health measures that aim to break the chain of pathogen transmission. Changes in viral characteristics of COVID-19 variants have likely affected the effectiveness of CICT programs. We estimated and compared the cases averted in Vermont when the original COVID-19 strain circulated (Nov. 25, 2020-Jan. 19, 2021) with two periods when the Delta strain dominated (Aug. 1-Sept. 25, 2021, and Sept. 26-Nov. 20, 2021). When the original strain circulated, we estimated that CICT prevented 7180 cases (55% reduction in disease burden), compared to 1437 (15% reduction) and 9970 cases (40% reduction) when the Delta strain circulated. Despite the Delta variant being more infectious and having a shorter latency period, CICT remained an effective tool to slow spread of COVID-19; while these viral characteristics did diminish CICT effectiveness, non-viral characteristics had a much greater impact on CICT effectiveness.

Identifiants

pubmed: 39090157
doi: 10.1038/s41598-024-68634-x
pii: 10.1038/s41598-024-68634-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17848

Informations de copyright

© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Eames, K. T. & Keeling, M. J. Contact tracing and disease control. Proc. Royal Soc. Lond. Series B Biol. Sci. 270(1533), 2565–2571 (2003).
doi: 10.1098/rspb.2003.2554
Jeon, S. et al. Estimates of cases and hospitalizations averted by COVID-19 case investigation and contact tracing in 14 health jurisdictions in the United States. J. Public Health Manag. Pract. 28(1), 16–24 (2022).
doi: 10.1097/PHH.0000000000001420 pubmed: 34534993
Rainisch, G. et al. Estimated COVID-19 cases and hospitalizations averted by case investigation and contact tracing in the US. JAMA Netw. Open 5(3), e224042–e224042 (2022).
doi: 10.1001/jamanetworkopen.2022.4042 pubmed: 35333362 pmcid: 8956978
Jeon, S. et al. Adapting COVID-19 contact tracing protocols to accommodate resource constraints, Philadelphia, Pennsylvania, USA, 2021. Emerg. Infect. Dis. 30(2), 333 (2024).
doi: 10.3201/eid3002.230988 pubmed: 38181801 pmcid: 10826771
Kraemer, M. U. et al. Monitoring key epidemiological parameters of SARS-CoV-2 transmission. Nat. Med. 27(11), 1854–1855 (2021).
doi: 10.1038/s41591-021-01545-w pubmed: 34750555
Bugalia, S., Tripathi, J. P. & Wang, H. Mutations make pandemics worse or better: Modeling SARS-CoV-2 variants and imperfect vaccination. arXiv preprint arXiv:2201.06285 , (2022).
Wang, Y. et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine 40, 101129 (2021).
doi: 10.1016/j.eclinm.2021.101129 pubmed: 34541481 pmcid: 8435265
Li, B. et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 delta variant. Nat. Commun. 13(1), 1–9 (2022).
Liu, Y. & Rocklov, J. The reproductive number of the delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J. Travel Med. 28(7), taab124 (2021).
doi: 10.1093/jtm/taab124 pubmed: 34369565 pmcid: 8436367
Alimohamadi, Y., Sepandi, M. & Esmaeilzadeh, F. Estimate of the basic reproduction number for Delta variant of SARS-CoV-2: A systematic review and meta-analysis. J. Biostat. Epidemiol. 8(1), 1–7 (2022).
U.S. Centers for Disease Control and Prevention, COVIDTracer and COVIDTracer advanced, 19 January 2021. [Online]. Available: https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/COVIDTracerTools.html . [Accessed 5 April 2023].
Jeon, S. et al. Estimated cases averted by COVID-19 electronic exposure notification–Pennsylvania, November 8, 2020 to January 2, 2021. Emerg. Infect. Dis. 29(2), 426 (2023).
doi: 10.3201/eid2902.220959 pubmed: 36639132 pmcid: 9881797
Castonguay, F. M. et al. Estimated public health impact of concurrent mask mandate and vaccinate-or-test requirement in Illinois, October to December 2021. BMC Public Health 24(1), 1013 (2024).
doi: 10.1186/s12889-024-18203-8 pubmed: 38609903 pmcid: 11010411
CoVariants (c) 2020–2023 Emma Hodcroft, CoVariants: SARS-CoV-2 Mutations and Variants of Interest. [Online]. Available: https://covariants.org/per-country?region=United+States&country=Vermont . [Accessed 5 April 2023].
Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N. Engl. J. Med. 385(7), 585–594 (2021).
doi: 10.1056/NEJMoa2108891 pubmed: 34289274
Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385(24), e84 (2021).
doi: 10.1056/NEJMoa2114583 pubmed: 34614326
Rosenblum, H. G. et al. Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines—United States, October 2022. MMWR Morb. Mortal. Wkly. Rep. 71(45), 1436–1441 (2022).
doi: 10.15585/mmwr.mm7145a2 pubmed: 36355612 pmcid: 9707353
Ma, X. et al. Contact tracing period and epidemiological characteristics of an outbreak of the SARS-CoV-2 Delta variant in Guangzhou. Int. J. Infectious Dis. 117, 18–23 (2022).
doi: 10.1016/j.ijid.2022.01.034
Nguyen, T.-P. et al. Rapid impact assessments of COVID-19 control measures against the Delta variant and short-term projections of new confirmed cases in Vietnam. J. Global Health 11, 03118 (2021).
doi: 10.7189/jogh.11.03118
Chiu, W. A. & Ndeffo-Mbah, M. L. Using test positivity and reported case rates to estimate state-level COVID-19 prevalence and seroprevalence in the United States. PLoS Comput. Biol. 17(9), e1009374 (2021).
doi: 10.1371/journal.pcbi.1009374 pubmed: 34491990 pmcid: 8448371
Lewis, D. Superspreading drives the COVID pandemic–and could help to tame it. Nature 590(7847), 544–547 (2021).
doi: 10.1038/d41586-021-00460-x pubmed: 33623168
Bugalia, S., Tripathi, J. P. & Wang, H. Mathematical modeling of intervention and low medical resource availability with delays: Applications to COVID-19 outbreaks in Spain and Italy. Math. Biosci. Eng. 18(5), 5865–5920 (2021).
doi: 10.3934/mbe.2021295 pubmed: 34517515
Borah, B. F. et al. High community transmission of SARS-CoV-2 associated with decreased contact tracing effectiveness for identifying persons at elevated risk of infection-vermont. Clin. Infectious Dis. 75(Supplement_2), S334–S337 (2022).
doi: 10.1093/cid/ciac518
Lash, R. R. et al. COVID-19 case investigation and contact tracing in the US, 2020. JAMA Netw. Open 4(6), e2115850–e2115850 (2021).
doi: 10.1001/jamanetworkopen.2021.15850 pubmed: 34081135 pmcid: 8176334
Xiang, Y. et al. COVID-19 epidemic prediction and the impact of public health interventions: A review of COVID-19 epidemic models. Infectious Dis. Modell. 6, 324–342 (2021).
doi: 10.1016/j.idm.2021.01.001
Centers for Disease Control and Prevention (CDC). COVID-19 Pandemic Planning Scenarios (U.S Department of Health and Human Services, 2020).
Liu, Y., Gayle, A. A., Wilder-Smith, A. & Rocklov, J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J. Travel Med. 1–4 (2020).
Centers for Disease Control and Prevention, COVID-19 Vaccinations in the United States, County, [Online]. Available: https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-County/8xkx-amqh . [Accessed 25 April 2023].
Tahamtan, A. & Ardebili, A. Real-time RT-PCR in COVID-19 detection: Issues affecting the results. Expert Rev. Mol. Diagn. 20(5), 453–454 (2020).
doi: 10.1080/14737159.2020.1757437 pubmed: 32297805
Bugalia, S., Tripathi, J. P. & Wang, H. Estimating the time-dependent effective reproduction number and vaccination rate for COVID-19 in the USA and India. Math. Biosci. Eng 20(3), 4673–4689 (2023).
doi: 10.3934/mbe.2023216 pubmed: 36896517
Smith, L. E., Potts, H. W., Amlot, R., Fear, N. T., Michie, S. & Rubin, G. J. Adherence to the test, trace, and isolate system in the UK: Results from 37 nationally representative surveys. BMJ 372(608), (2021).
Park, C. L. et al. Americans’ COVID-19 stress, coping, and adherence to CDC guidelines. J. General Intern. Med. 35(8), 2296–2303 (2020).
doi: 10.1007/s11606-020-05898-9
Pew Research Center, The Challenges of Contact Tracing as U.S. Battles COVID-19. Washington D.C., (2020).
Castonguay, F. M. et al. Building a simple model to assess the impact of case investigation and contact tracing for sexually transmitted diseases: Lessons From COVID-19. AJPM Focus 3(1), 100147 (2024).
doi: 10.1016/j.focus.2023.100147 pubmed: 38149077
Akman, O. et al. The hard lessons and shifting modeling trends of COVID-19 dynamics: Multiresolution modeling approach. Bull. Math. Biol. 84, 1–30 (2022).
doi: 10.1007/s11538-021-00959-4
Chen, M. et al. The introduction of population migration to SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. Inf. Fusion 64, 252–258 (2020).
doi: 10.1016/j.inffus.2020.08.002 pubmed: 32834796 pmcid: 7406520
Edridge, A. W. et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med. 26(11), 1691–1693 (2020).
doi: 10.1038/s41591-020-1083-1 pubmed: 32929268

Auteurs

François M Castonguay (FM)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA. francois.castonguay@umontreal.ca.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA. francois.castonguay@umontreal.ca.
Department of Health Management, Evaluation and Policy, University of Montreal School of Public Health, and Centre for Public Health Research - CReSP, 7101 Avenue du Parc, 3e étage, Montréal, QC, H3N 1X9, Canada. francois.castonguay@umontreal.ca.

Brian F Borah (BF)

Vermont Department of Health, Burlington, USA.
Epidemic Intelligence Service, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Seonghye Jeon (S)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Gabriel Rainisch (G)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Patsy Kelso (P)

Vermont Department of Health, Burlington, USA.

Bishwa B Adhikari (BB)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Daniel J Daltry (DJ)

Vermont Department of Health, Burlington, USA.

Leah S Fischer (LS)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Bradford Greening (B)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Emily B Kahn (EB)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Gloria J Kang (GJ)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Martin I Meltzer (MI)

National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, Health Economics and Modeling Unit, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.
Modeling Support Team, Contact Tracing and Innovation Section (CTIS), State Local Tribal and Territorial (STLT) Task Force, CDC COVID-19 Response; Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH